October is likely to be the quietest month of 2024 in terms of SPAC partners coming unglued from their lock-up agreements, and it comes right on the heels of the most-watched lock-up expiry in quite some time. More
Jackson II (NYSE:JACS.U) has filed for a $200 million SPAC with improved terms over the team's last vehicle, which liquidated in 2023 without a having signed a deal. This SPAC would have some structures from the standard set of mid-2024 filings as it will not overfund its trust with $10. More
Although it is last day of the September, SPACs still have business on the docket for the third quarter with both a completion vote and an extension vote today. More
Terms Tracker for the Week Ending September 27, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week's pricings. Surprisingly, last week was fairly quiet. More
Three more SPACs are now posed to come off of the board with one each in the deal approval, closing or liquidation category. Nonetheless, there is still unfinished business for the waning days of the third quarter as this morning will bring updated inflation readings on core PCE prices, personal consumption and personal income. More
The third quarter of 2024 has been big for terminated deals with 18 transactions broken up so far. Half of these fell apart in August but three more have added to the rolls in September. More
Charlton Aria (NASDAQ:CHARU) helps pick up the pace in new SPAC filings as its bid for a $75 million IPO becomes the fourth new entry in the past week after no SPACs filed in the first half of the September. More
Breeze Holdings Acquisition Corp. (OTC:BRZH) has entered into a definitive agreement to combine with drug developer YD Biopharma at an enterprise value of $694 million. Taipei-based YD is developing a trio of treatment candidates meant to treat some eye conditions and screen for pancreatic and breast cancer, whose patents it has under license. More
As discussed yesterday, the early release of Trump Media's (NASDAQ:DJT) lock-ups has not quite been the disaster foretold and the company is up a further +6% in the pre-market above $13. More
Company and sponsor shareholders in this year's buzziest de-SPAC have now been set free from the most anticipated early lock-up expiration release, but the change has arguably so far been less dramatic than the buildup. More
